TABLE 1.
Animal study designa
| Study | Groupb | Vaccine platform (antigenic cluster) | Challenge virus (antigenic cluster) | No. of pigs |
|---|---|---|---|---|
| 1 | NV-NC | No vaccine | No challenge | 8 |
| NV-IN/13 | No vaccine | IN/13 (red) | 8 | |
| OH/04WIV-IN/13 | OH/04WIV (cyan) | IN/13 (red) | 8 | |
| OH/04LAIV-IN/13 | OH/04LAIV (cyan) | IN/13 (red) | 8 | |
| 2 | NV-NC | No vaccine | No challenge | 5 |
| NV-IA/14 | No vaccine | IA/14 (green) | 10 | |
| IA/14WIV-IA/14 | IA/14WIV (green) | IA/14 (green) | 10 | |
| IA/14LAIV-IA/14 | IA/14LAIV (green) | IA/14 (green) | 10 | |
| NV-NY/11 | No vaccine | NY/11 (red) | 9 | |
| IA/14WIV-NY/11 | IA/14WIV (green) | NY/11 (red) | 10 | |
| IA/14LAIV-NY/11 | IA/14LAIV (green) | NY/11 (red) | 10 |
a
NV, nonvaccinated; NC, nonchallenged; WIV, adjuvanted-whole inactivated virus vaccine; LAIV, live-attenuated influenza A virus vaccine.
b
The vaccine and challenge strains used in each group are indicated.